Feven W. Getaneh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Feven W. Getaneh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Alexis A. Dieter
Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, USA
4 shared publicationsCheryl B. Iglesia
Department of Obstetrics and Gynecology, Medstar National Center for Advanced Pelvic Surgery
3 shared publicationsLee Ann Richter
Department of Obstetrics and Gynecology, Department of Urology, Medstar Georgetown University Hospital, Washington, USA
2 shared publicationsPaul Kolm
Medstar Heath Research Institute
2 shared publicationsSerenity Budd
MedStar Health Research Institute, Columbia, USA
2 shared publicationsAlexis Dieter
Department of Obstetrics and Gynecology, MedStar Washington Hospital Center, Washington, USA
1 shared publication
Latest Publications
- 10 November 2025
- Published by Springer Nature in International Urogynecology Journal
- Vol. 37 (3) , 649-654
Trends of Genitourinary Fistula in Kigali, Rwanda, over a 10-year Period
Genitourinary (GU) fistula most commonly occurs following ischemic damage during protracted labor or iatrogenic injury at time of surgery. Many developing nations report high rates of ischemic fistula, in part due to limited healthcare access. We aimed to assess the etiology and trends of genitourinary fistula in Rwanda over a 10-year period. Retrospective chart review of women presenting for management of fistula in Kigali, Rwanda, between 2013 and 2024. Iatrogenic etiology was defined as those temporally following cesarean section or hysterectomy and included vesico-uterine, vesico-cervical, uretero-vaginal, vesico-vaginal at vaginal cuff, or high vesico-vaginal fistula. All other GU fistula were assigned as ischemic. There were 909 women diagnosed with GU fistula with 416 (46%) characterized as iatrogenic and 493 (54%) as ischemic fistula. Iatrogenic fistula had significantly higher proportions of abdominal routes for repair (40% vs 5%) and abdominal hysterectomies performed (26% vs 5%) compared to ischemic fistulas (p < 0.001). Ischemic fistula were more likely to be recommended for urinary diversion (29% vs. 4%, p < 0.001). There was a significant increase in iatrogenic fistula over time with a 2.1% increase per year (p < 0.001) (Fig. 1). There were 279 women with recurrent GU fistula with a significantly higher proportion of ischemic fistula with recurrence (p < 0.001). There was a significant increase in iatrogenic fistula over a 10-year period in Rwanda resulting from obstetrical and gynecological surgeries. Iatrogenic fistula were more likely to require a more invasive surgical approach while ischemic fistula were more likely to either be recommended for urinary diversion or present with recurrence following repair.
- 10 November 2025
- Published by Springer Nature in International Urogynecology Journal
- Vol. 37 (3) , 649-654
Trends of Genitourinary Fistula in Kigali, Rwanda, over a 10-year Period
Genitourinary (GU) fistula most commonly occurs following ischemic damage during protracted labor or iatrogenic injury at time of surgery. Many developing nations report high rates of ischemic fistula, in part due to limited healthcare access. We aimed to assess the etiology and trends of genitourinary fistula in Rwanda over a 10-year period. Retrospective chart review of women presenting for management of fistula in Kigali, Rwanda, between 2013 and 2024. Iatrogenic etiology was defined as those temporally following cesarean section or hysterectomy and included vesico-uterine, vesico-cervical, uretero-vaginal, vesico-vaginal at vaginal cuff, or high vesico-vaginal fistula. All other GU fistula were assigned as ischemic. There were 909 women diagnosed with GU fistula with 416 (46%) characterized as iatrogenic and 493 (54%) as ischemic fistula. Iatrogenic fistula had significantly higher proportions of abdominal routes for repair (40% vs 5%) and abdominal hysterectomies performed (26% vs 5%) compared to ischemic fistulas (p < 0.001). Ischemic fistula were more likely to be recommended for urinary diversion (29% vs. 4%, p < 0.001). There was a significant increase in iatrogenic fistula over time with a 2.1% increase per year (p < 0.001) (Fig. 1). There were 279 women with recurrent GU fistula with a significantly higher proportion of ischemic fistula with recurrence (p < 0.001). There was a significant increase in iatrogenic fistula over a 10-year period in Rwanda resulting from obstetrical and gynecological surgeries. Iatrogenic fistula were more likely to require a more invasive surgical approach while ischemic fistula were more likely to either be recommended for urinary diversion or present with recurrence following repair.
- 1 December 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (6) , 3289-3296
The effect of breastfeeding on postpartum sexual function: an observational cohort study
Purpose Postpartum women commonly experience sexual dysfunction; however, little is known regarding the effect of breastfeeding on sexual function and postpartum women’s interest in treatment. We aimed to evaluate sexual function and genitourinary symptoms based on infant-feeding status and assess desire for treatment. Methods Cross-sectional observational study of women 5–6 months postpartum following singleton delivery was performed. Participants were grouped based on self-reported infant-feeding status: (1) primarily breastfeeding (BF) and (2) primarily formula feeding (FF). Female Sexual Function Index (FSFI) and Day-to-day Impact on Vaginal Aging (DIVA) questionnaires and interest in treatment were compared. Results In total, 125 women were included with 61 (49%) breastfeeding and 64 (51%) formula feeding. Compared to FF women, BF women were less likely to identify as African American (47% vs 79%; SD 0.8) or have Medicaid (28% vs 66%; SD 0.9). No other large differences were noted. BF women had significantly lower FSFI score indicating poorer sexual function (20.8 (IQR 10, 24) BF vs 24.5 (IQR 19.5, 27.8) FF, p = 0.009). Both cohorts reported low bother from vaginal symptoms and low interest in treatment of symptoms with BF cohort reporting higher interest in use of vaginal lubricants (69% BF vs 30% FF, SD 0.8). Factors associated with lower FSFI score were BF, perineal laceration, use of progesterone long-acting reversible contraception, and single relationship status. Conclusion Both breastfeeding and formula feeding women experienced high rates of sexual dysfunction but low bother from vaginal symptoms and low interest in treatment. Further research is needed to explore these findings and assess postpartum sexual health.
- 1 December 2024
- Published by Springer Nature in Archives of Gynecology and Obstetrics
- Vol. 310 (6) , 3289-3296
The effect of breastfeeding on postpartum sexual function: an observational cohort study
Purpose Postpartum women commonly experience sexual dysfunction; however, little is known regarding the effect of breastfeeding on sexual function and postpartum women’s interest in treatment. We aimed to evaluate sexual function and genitourinary symptoms based on infant-feeding status and assess desire for treatment. Methods Cross-sectional observational study of women 5–6 months postpartum following singleton delivery was performed. Participants were grouped based on self-reported infant-feeding status: (1) primarily breastfeeding (BF) and (2) primarily formula feeding (FF). Female Sexual Function Index (FSFI) and Day-to-day Impact on Vaginal Aging (DIVA) questionnaires and interest in treatment were compared. Results In total, 125 women were included with 61 (49%) breastfeeding and 64 (51%) formula feeding. Compared to FF women, BF women were less likely to identify as African American (47% vs 79%; SD 0.8) or have Medicaid (28% vs 66%; SD 0.9). No other large differences were noted. BF women had significantly lower FSFI score indicating poorer sexual function (20.8 (IQR 10, 24) BF vs 24.5 (IQR 19.5, 27.8) FF, p = 0.009). Both cohorts reported low bother from vaginal symptoms and low interest in treatment of symptoms with BF cohort reporting higher interest in use of vaginal lubricants (69% BF vs 30% FF, SD 0.8). Factors associated with lower FSFI score were BF, perineal laceration, use of progesterone long-acting reversible contraception, and single relationship status. Conclusion Both breastfeeding and formula feeding women experienced high rates of sexual dysfunction but low bother from vaginal symptoms and low interest in treatment. Further research is needed to explore these findings and assess postpartum sexual health.
- 14 November 2024
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 31 (3) , 194-200
Botox for Sleep Effectiveness
Importance: Nocturia is one of the most bothersome complaints in women with overactive bladder syndrome (OAB). Although small preliminary studies have shown that intradetrusor onabotulinum toxin A (BTX) injections reduce nocturia episodes, it is not known how reduction in nighttime urination affects sleep quality and quality of life. Objectives: We aimed to assess the effect of BTX on nocturia frequency, sleep quality, and quality of life. Study Design: This is a prospective observation study of adult women with ≥2 nocturia episodes and OAB planning to undergo treatment with BTX injections. Participants completed a 2-day bladder/sleep diary and sleep-related questionnaires at baseline and 5 weeks post-BTX. Results: A total of 40 participants were included with a mean age of 71 ± 12 years and most (90%) undergoing 100 units of BTX injection. At baseline, the median nocturia episodes were 3.5 (IQR, 2.5–5.0), and nearly half (43%) of participants reported mild to moderate sleep disturbance. At 5 weeks post-BTX, we found a significant decrease in nocturia episodes (−2/night) and a 59% decrease in mild to moderate sleep disturbance (P = 0.006). There were significant increases in longest sleep interval (+1.5 hours), time to first awakening (+1.6 hours) and average sleep interval (+1.3 hours), and a significant increase in nocturia-related quality of life scores (P < 0.001 for all). Sixteen (40%) of participants had nocturia resolution defined as ≤1 mean nocturia episode post-BTX. Conclusions: For women with OAB and >2 nocturia episodes/night, BTX injections reduce voids/night and improve sleep quality and nocturia-related quality of life.
- 14 November 2024
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 31 (3) , 194-200
Botox for Sleep Effectiveness
Importance: Nocturia is one of the most bothersome complaints in women with overactive bladder syndrome (OAB). Although small preliminary studies have shown that intradetrusor onabotulinum toxin A (BTX) injections reduce nocturia episodes, it is not known how reduction in nighttime urination affects sleep quality and quality of life. Objectives: We aimed to assess the effect of BTX on nocturia frequency, sleep quality, and quality of life. Study Design: This is a prospective observation study of adult women with ≥2 nocturia episodes and OAB planning to undergo treatment with BTX injections. Participants completed a 2-day bladder/sleep diary and sleep-related questionnaires at baseline and 5 weeks post-BTX. Results: A total of 40 participants were included with a mean age of 71 ± 12 years and most (90%) undergoing 100 units of BTX injection. At baseline, the median nocturia episodes were 3.5 (IQR, 2.5–5.0), and nearly half (43%) of participants reported mild to moderate sleep disturbance. At 5 weeks post-BTX, we found a significant decrease in nocturia episodes (−2/night) and a 59% decrease in mild to moderate sleep disturbance (P = 0.006). There were significant increases in longest sleep interval (+1.5 hours), time to first awakening (+1.6 hours) and average sleep interval (+1.3 hours), and a significant increase in nocturia-related quality of life scores (P < 0.001 for all). Sixteen (40%) of participants had nocturia resolution defined as ≤1 mean nocturia episode post-BTX. Conclusions: For women with OAB and >2 nocturia episodes/night, BTX injections reduce voids/night and improve sleep quality and nocturia-related quality of life.
- 7 March 2024
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 30 (3) , 264-271
Comparing Impact of Overactive Bladder Therapies on Nocturia
Importance: Nocturia is a significant symptom in overactive bladder with little data regarding the impact of overactive bladder treatments on nocturia. Objectives: Compare the effect of anticholinergic (AC) medication, onabotulinum toxin A (BTX), and sacral neuromodulation (SNM) on nocturia. Study Design: Secondary analysis of the ABC and ROSETTA trials using data from the National Institutes of Health Data and Specimen Hub database. Patients reporting mean ≥2 voids/night on 3-day diary were included and divided into cohorts by treatment: the ABC trial: (1) AC and (2) BTX 100 units, and the ROSETTA trial: (3) BTX 200 units and (4) SNM. Primary outcome was change in mean voids/night on 3-day diary from baseline to 6 months assessed by mixed-effects models for repeated-measures data with interaction between treatment cohort and time included in model. Results: A total of 197 patients were included: 43 (22%) AC, 37 (19%) BTX 100 U, 63 (32%) BTX 200 U, and 54 (27%) SNM. There were no significant differences in baseline voids/night, demographics, or urodynamic values except for younger age in AC and BTX 100 U cohorts (P = 0.04). At 6 months, all cohorts demonstrated a mean 41% decrease in mean voids/night (2.7 ± 0.4 at baseline to 1.6 ± 0.5 at 6 months; P < 0.001), with no significant difference in change in mean voids/night between treatment cohorts (decrease of 44% in AC, 46% in 100 U BTX, 32% 200 in U BTX, and 33% in SNM; P > 0.05). Conclusion: For women with nocturia ≥2/night, treatment with AC, BTX 100 or 200 units, or SNM led to a significant decrease in voids/night at 6 months.
- 7 March 2024
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 30 (3) , 264-271
Comparing Impact of Overactive Bladder Therapies on Nocturia
Importance: Nocturia is a significant symptom in overactive bladder with little data regarding the impact of overactive bladder treatments on nocturia. Objectives: Compare the effect of anticholinergic (AC) medication, onabotulinum toxin A (BTX), and sacral neuromodulation (SNM) on nocturia. Study Design: Secondary analysis of the ABC and ROSETTA trials using data from the National Institutes of Health Data and Specimen Hub database. Patients reporting mean ≥2 voids/night on 3-day diary were included and divided into cohorts by treatment: the ABC trial: (1) AC and (2) BTX 100 units, and the ROSETTA trial: (3) BTX 200 units and (4) SNM. Primary outcome was change in mean voids/night on 3-day diary from baseline to 6 months assessed by mixed-effects models for repeated-measures data with interaction between treatment cohort and time included in model. Results: A total of 197 patients were included: 43 (22%) AC, 37 (19%) BTX 100 U, 63 (32%) BTX 200 U, and 54 (27%) SNM. There were no significant differences in baseline voids/night, demographics, or urodynamic values except for younger age in AC and BTX 100 U cohorts (P = 0.04). At 6 months, all cohorts demonstrated a mean 41% decrease in mean voids/night (2.7 ± 0.4 at baseline to 1.6 ± 0.5 at 6 months; P < 0.001), with no significant difference in change in mean voids/night between treatment cohorts (decrease of 44% in AC, 46% in 100 U BTX, 32% 200 in U BTX, and 33% in SNM; P > 0.05). Conclusion: For women with nocturia ≥2/night, treatment with AC, BTX 100 or 200 units, or SNM led to a significant decrease in voids/night at 6 months.
- 8 November 2023
- Published by Springer Nature in International Urogynecology Journal
- Vol. 35 (1) , 19-29
Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis
Introduction and hypothesis To our knowledge, there are no evidence-based recommendations regarding the optimal prophylactic antibiotic regimen for intradetrusor onabotulinum toxin type A (BTX) injections. This systematic review and meta-analysis was aimed at investigating the optimal prophylactic antibiotic regimen to decrease urinary tract infection (UTI) in patients undergoing BTX for overactive bladder syndrome (OAB). Methods A systematic search of MEDLINE, Embase, CINAHL, and Web of Science was conducted from inception through 30 June 2022. All randomized controlled trials and prospective trials with > 20 subjects undergoing BTX injections for OAB in adults that described prophylactic antibiotic regimens were included. Meta-analysis performed to assess UTI rates in patients with idiopathic OAB using the inverse variance method for pooling. Results A total of 27 studies (9 randomized controlled trials, 18 prospective) were included, representing 2,100 patients (69% women) with 19 studies of idiopathic OAB patients only, 6 of neurogenic only, and 2 including both. No studies directly compared antibiotic regimens for the prevention of UTI. Included studies favor the use of antibiotics in patients with idiopathic OAB and favor continuing antibiotics for 2–3 days after the procedure for prevention of UTI. Given the heterogeneity of the data, direct comparisons of antibiotic type or duration could not be performed. Meta-analysis found a 10% UTI rate at 4 weeks and 15% at 12 weeks post-injection. Conclusions Although there are insufficient data to support the use of a specific antibiotic regimen, available studies favor the use of prophylactic antibiotics for 2–3 days in idiopathic OAB patients undergoing BTX injection. Future trials are needed to determine the optimal regimens to prevent UTI in patients undergoing BTX for OAB.
- 8 November 2023
- Published by Springer Nature in International Urogynecology Journal
- Vol. 35 (1) , 19-29
Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis
Introduction and hypothesis To our knowledge, there are no evidence-based recommendations regarding the optimal prophylactic antibiotic regimen for intradetrusor onabotulinum toxin type A (BTX) injections. This systematic review and meta-analysis was aimed at investigating the optimal prophylactic antibiotic regimen to decrease urinary tract infection (UTI) in patients undergoing BTX for overactive bladder syndrome (OAB). Methods A systematic search of MEDLINE, Embase, CINAHL, and Web of Science was conducted from inception through 30 June 2022. All randomized controlled trials and prospective trials with > 20 subjects undergoing BTX injections for OAB in adults that described prophylactic antibiotic regimens were included. Meta-analysis performed to assess UTI rates in patients with idiopathic OAB using the inverse variance method for pooling. Results A total of 27 studies (9 randomized controlled trials, 18 prospective) were included, representing 2,100 patients (69% women) with 19 studies of idiopathic OAB patients only, 6 of neurogenic only, and 2 including both. No studies directly compared antibiotic regimens for the prevention of UTI. Included studies favor the use of antibiotics in patients with idiopathic OAB and favor continuing antibiotics for 2–3 days after the procedure for prevention of UTI. Given the heterogeneity of the data, direct comparisons of antibiotic type or duration could not be performed. Meta-analysis found a 10% UTI rate at 4 weeks and 15% at 12 weeks post-injection. Conclusions Although there are insufficient data to support the use of a specific antibiotic regimen, available studies favor the use of prophylactic antibiotics for 2–3 days in idiopathic OAB patients undergoing BTX injection. Future trials are needed to determine the optimal regimens to prevent UTI in patients undergoing BTX for OAB.
- 26 September 2023
- Published by Springer Nature in International Urogynecology Journal
- Vol. 34 (11) , 2809-2816
The effect of 12-month postoperative weight change on outcomes following midurethral sling for stress urinary incontinence: a secondary analysis of the ESTEEM and TOMUS randomized trials
Introduction and hypothesis Prior studies demonstrate mixed results on the impact of obesity on the success of midurethral slings (MUS), with little known about how postoperative weight change affects outcomes. We aimed to examine the effect of postoperative weight change on outcomes 12 months after MUS for stress urinary incontinence (SUI). Methods This secondary analysis utilized data from two multicenter randomized trials of women undergoing MUS placement. Subjects were categorized into cohorts based on change in body weight at 12 months postoperatively: weight gain (≥5% increase); weight loss (≥5% decrease), and weight stable (p = 0.607). Of 372 subjects with MUI, the weight loss cohort had significantly greater improvement in UUI episodes. Conclusions Weight change at 12 months postoperatively did not significantly alter efficacy of MUS for treatment of SUI. Patients with MUI who lost ≥5% body weight had significantly greater improvement in UUI episodes.
- 26 September 2023
- Published by Springer Nature in International Urogynecology Journal
- Vol. 34 (11) , 2809-2816
The effect of 12-month postoperative weight change on outcomes following midurethral sling for stress urinary incontinence: a secondary analysis of the ESTEEM and TOMUS randomized trials
Introduction and hypothesis Prior studies demonstrate mixed results on the impact of obesity on the success of midurethral slings (MUS), with little known about how postoperative weight change affects outcomes. We aimed to examine the effect of postoperative weight change on outcomes 12 months after MUS for stress urinary incontinence (SUI). Methods This secondary analysis utilized data from two multicenter randomized trials of women undergoing MUS placement. Subjects were categorized into cohorts based on change in body weight at 12 months postoperatively: weight gain (≥5% increase); weight loss (≥5% decrease), and weight stable (p = 0.607). Of 372 subjects with MUI, the weight loss cohort had significantly greater improvement in UUI episodes. Conclusions Weight change at 12 months postoperatively did not significantly alter efficacy of MUS for treatment of SUI. Patients with MUI who lost ≥5% body weight had significantly greater improvement in UUI episodes.
- 29 June 2023
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 229 (3) , 284.e1-284.e10
Disparities in adherence to retesting guidelines in women with Trichomonas vaginalis infection
- 29 June 2023
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 229 (3) , 284.e1-284.e10
Disparities in adherence to retesting guidelines in women with Trichomonas vaginalis infection
- 19 May 2023
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 29 (8) , 657-659
Race in Clinical Algorithms and Calculators in Urogynecology: What Is Glaring to Us
- 19 May 2023
- Published by Wolters Kluwer Health in Urogynecology
- Vol. 29 (8) , 657-659
Race in Clinical Algorithms and Calculators in Urogynecology: What Is Glaring to Us